Good news leads to spike
Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular carcinoma (HCC) who had not responded to first-line treatment with kinase inhibitor Nexavar. In the study, resminostat was administered alone and in combination with Nexavar. In 24 evaluable patients, the treatments led to progression-free survival of 33.3% (resminostat alone) and 66.6% (combination therapy) after 12 weeks. Resminostat is an oral pan-histone deacetylase (HDAC) inhibitor. 4SC said it plans to consult regulatory authorities in the US and EU on advice for a pivotal trial with the substance. Last September, resminostat met the primary endpoint of overall response rate in a Phase II SAPHIRE trial to treat Hodgkin’s lymphoma. The drug was originally invented by German pharma Altana AG, which was acquired by Nycomed. 4SC used the windfall to buy assets left over following the restructuring of Altana’s former oncology portfolio.